APA (7th ed.) Citation

V, R., ED, N., M, D., V, N., MP, Y., AD, A., . . . E, D. (2026). Modeling rebound bone loss following denosumab discontinuation and sequential zoledronate therapy in TgRANKL osteoporotic mice. Frontiers in endocrinology, 17, 1783656. https://doi.org/10.3389/fendo.2026.1783656

Chicago Style (17th ed.) Citation

V, Rinotas, Ntouskou ED, Dragolia M, Ntafis V, Yavropoulou MP, Anastasilakis AD, Makras P, and Douni E. "Modeling Rebound Bone Loss Following Denosumab Discontinuation and Sequential Zoledronate Therapy in TgRANKL Osteoporotic Mice." Frontiers in Endocrinology 17 (2026): 1783656. https://doi.org/10.3389/fendo.2026.1783656.

MLA (9th ed.) Citation

V, Rinotas, et al. "Modeling Rebound Bone Loss Following Denosumab Discontinuation and Sequential Zoledronate Therapy in TgRANKL Osteoporotic Mice." Frontiers in Endocrinology, vol. 17, 2026, p. 1783656, https://doi.org/10.3389/fendo.2026.1783656.